Comprehensive Analyses of Circulating Cell- Free Tumor DNA
|
|
- Meagan Gaines
- 5 years ago
- Views:
Transcription
1 Comprehensive Analyses of Circulating Cell- Free Tumor DNA Boston, MA June 28th, 2016 Derek Murphy, Ph.D. Scientist, Research and Development Personal Genome Diagnostics
2 Acquisition of Somatic Alterations Throughout Tumorigenesis Sci Transl Med February 24; 2(20): 20ra14. Nat Med September; 14(9): B Vogelstein et al. Science 2013;339:
3 Circulating Cell-Free Tumor DNA The presence of cell-free DNA in the circulation was first formally described by Mandel and Metais in ctdna can be detected across many common solid tumor types in patients in both early and late stages of cancer, with levels ranging from less than one to greater than 100,000 mutant DNA fragments per milliliter of plasma. DNA fragments of bp with half life of several hours Genetic alterations are specific to the tumor Real-time, non-invasive, multi-lesions Unlike other tumor biomarkers, the specificity of somatic alterations is derived from the fact that mutations are present in the genome(s) of tumor cells but not in the genome of matched normal cells. Nat Rev Cancer Jun;11(6):
4 Circulating Tumor DNA is Detectable Across Tumor Types with Rearrangements and Sequence Mutations Sci Transl Med Feb 19;6(224):224ra24. 4
5 Applications of Circulating Tumor DNA Sci Transl Med Feb 19;6(224):224ra24. 5
6 Technologies for Detection of Genomic Alterations in cfdna Single-Base Sequence Alterations Digital PCR Enrichment of Mutant DNA Ice-Cold PCR, PCR-Clamping, etc Specific Domains or Regions of Genes for Detection of Sequence Mutations Amplicon-Based, Molecular Barcoding and Next-Generation Sequencing Large Panels for Detection of Sequence Mutations, Copy Number Alterations and Translocations In-Solution Capture, Molecular Barcoding and Next-Generation Sequencing 6
7 PlasmaSelect Platform *Recurrently mutated exons were evaluated through a comprehensive analysis of COSMIC across all tumor types 7
8 Identification of Somatic Mutations with PlasmaSelect SureSelect Target Enrichment 8
9 Observed Allele Fraction (%) Detection of Sequence Mutations at Varying Levels of Tumor Contribution Using PlasmaSelect In-Solution Capture Technology % 51.20% 25.60% 12.80% 6.40% 3.20% 1.60% 0.80% 0.40% 0.20% 0.10% Limit of Detection = 0.10% 0.05% 0.05% 0.10% 0.20% 0.40% 0.80% 1.60% 3.20% 6.40% 12.80% 25.60% 51.20% % Expected Allele Fraction (%) A breast cancer tumor was diluted with matched wild-type DNA to 0.10%, 0.20%, 0.50%, 1.0%, 10%, 25%, 50% and 100% tumorderived DNA (0.10%, 0.20%, and 0.50% were evaluated in triplicate). For each sequence mutation, the observed allele fraction for the mutations identified in each case are plotted against the expected mutation allele fraction for that case. 9
10 Identification of Translocations at Varying Levels of Tumor Contribution 100% 10% 1% 1% 0.2% 0.2% 0.2% 0.1% 0.1% The chronic myeloid leukemia cell line 562 was titrated with wild-type DNA to 0.10%, 0.20%, 0.50%, 1.0%, 10%, 25%, 50% and 100% tumor-derived DNA (0.10%, 0.20%, and 0.50% were evaluated in triplicate). 10
11 A Case Study with Epizyme Development and application of a 62 gene panel for assessment of somatic sequence and structural variants in tumor DNA derived from non-hodgkin lymphoma.
12 NHL Study Background Tazemetostat is a small molecule inhibitor of the histone methyltransferase EZH2 and is being developed for the treatment of patients with non-hodgkin lymphoma and for patients with certain genetically defined solid tumors. Activating EZH2 mutations present in NHL patients have been implicated to predict response to EZH2 inhibition (Knutson et al. Nat Chem Biol. 2012) A Phase 1 clinical trial of tazemetostat demonstrated clinical responses in both EZH2 mutant and wild-type patients (NCT ) Epizyme and PGDx collaborated to build a custom panel for somatic mutation detection in ctdna of NHL patients for discovery of candidate biomarkers of response to tazemetostat Daigle et. al., 2016 AACR 12
13 NHL Study Design Development of a 62 gene panel designed to include previously identified variants occurring in NHL at >5% frequency. Analytically validated panel using a tumor cell line containing a subset of the variants of interest. Archive and ctdna collected from sixteen relapsed refractory NHL patients treated in the phase 1 clinical trial with tazemetostat. DNA was isolated from unstained FFPE slides and plasma derived from peripheral blood. Captured libraries were screened utilizing the Illumina HiSeq 2500 platform with 100 bp pairedend reads and analyzed using the PlasmaSelect pipeline. Daigle et. al., 2016 AACR 13
14 Lymphoma PlasmaSelect Panel Design Custom Lymphoma PlasmaSelect Sequence & Structural Gene List Gene Name Region(s) Included Gene Name Region(s) Included PRDM1 Full Coding Sequence KIT Specific Exon(s) EZH2 Full Coding Sequence KRAS Specific Exon(s) KDM6A Full Coding Sequence MEF2B Specific Exon(s) KMT2D Full Coding Sequence MYC Specific Exon(s) ARID1A Specific Exon(s) MYD88 Specific Exon(s) ATM Specific Exon(s) NOTCH1 Specific Exon(s) B2M Specific Exon(s) NOTCH2 Specific Exon(s) BCL2 Specific Exon(s) NRAS Specific Exon(s) BCL6 Specific Exon(s) PIK3CA Specific Exon(s) BCL7A Specific Exon(s) PIM1 Specific Exon(s) BRAF Specific Exon(s) POU2F2 Specific Exon(s) BTG1 Specific Exon(s) PTEN Specific Exon(s) CARD11 Specific Exon(s) PTPN1 Specific Exon(s) CCND3 Specific Exon(s) PTPN11 Specific Exon(s) CD58 Specific Exon(s) PTPN6 Specific Exon(s) CD79B Specific Exon(s) PTPRD Specific Exon(s) CDKN2A Specific Exon(s) RB1 Specific Exon(s) CREBBP Specific Exon(s) S1PR2 Specific Exon(s) EP300 Specific Exon(s) SGK1 Specific Exon(s) FOXO1 Specific Exon(s) SMARCB1 Specific Exon(s) GNA13 Specific Exon(s) SOCS1 Specific Exon(s) HIST1H1B Specific Exon(s) STAT6 Specific Exon(s) HIST1H1C Specific Exon(s) TBL1XR1 Specific Exon(s) HIST1H1E Specific Exon(s) TNFAIP3 Specific Exon(s) IKZF3 Specific Exon(s) TNFRSF14 Specific Exon(s) IRF4 Specific Exon(s) TP53 Specific Exon(s) ITPKB Specific Exon(s) XPO1 Specific Exon(s) Gene Name Region(s) Included Gene Name Region(s) Included ALK ALK_NM_004304_Intron19 CIITA Entire Gene BCL2 BCL2_MCR_Breakpoint_Region MYC Entire Gene + 40kbp upstream BCL2 BCL2_MBR_Breakpoint_Region CD274 (PDL1) Entire Gene BCL6 Entire Gene PDCD1LG2 (PDL2) Entire Gene Custom Lymphoma PlasmaSelect Amplification Gene List Gene Name BCL2 CD274 (PDL1) FOXP1 JAK2 KDM4C PDCD1LG2 (PDL2) REL 54 Target Genes for Sequence Mutations 8 Target Genes for Structural Alterations 7 Target Genes for Amplifications Daigle et. al., 2016 AACR 14
15 Mutation Allele Fraction Development of Cell-Free DNA Lymphoma Panel for Sequence Mutation Analyses Pre-Correction % Background Error Rate 25% Tumor Specimen 10% Tumor Specimen 1% Tumor Specimen 0.2% Tumor Specimen (Replicate 1) 0.2% Tumor Specimen (Replicate 2) 0.1% Tumor Specimen (Replicate 1) 0.1% Tumor Specimen (Replicate 2) 10.00% 1.00% 0.10% 0.01% Position in Targeted Region of Interest (bp) Daigle et. al., 2016 AACR 15
16 Mutation Allele Fraction Development of Cell-Free DNA Lymphoma Panel for Sequence Mutation Analyses Post-Correction % Background Error Rate 25% Tumor Specimen 10% Tumor Specimen 1% Tumor Specimen 0.2% Tumor Specimen (Replicate 1) 0.2% Tumor Specimen (Replicate 2) 0.1% Tumor Specimen (Replicate 1) 0.1% Tumor Specimen (Replicate 2) 10.00% 1.00% 0.10% 0.01% Position in Targeted Region of Interest (bp) Daigle et. al., 2016 AACR 16
17 Lymphoma PlasmaSelect Results NGS panel able to detect molecular amplifications, translocations and sequence mutations down to variant allele frequencies of 2% and 0.1% for archive and ctdna respectively. Sequencing of phase 1 NHL patients revealed a complex genetic landscape with epigenetic modifiers CREBBP and KMT2D representing the most frequently mutated genes in this sample set. 100% concordance with previously reported somatic mutations detected in archive tumor demonstrates panels reproducibility and utility. Demonstrates the ability to determine molecular profiles using ctdna, potentially enabling patient characterization where archive tumor is absent or limiting. Daigle et. al., 2016 AACR 17
18 Detection of Focal Gene Amplification in cfdna Identification of MET amplification through analyses of plasma DNA. The amplification of each gene is indicated as fold copy gain, along with the genomic rearrangements detected through whole-genome analyses of cell-free DNA obtained from plasma. Rearrangements associated with focal copy number alterations, including amplification of MET, are highlighted in red. (taken from Diaz et. al., Oncotarget Oct;4(10): ). 18
19 Evaluation of MET Amplification in Dilution Series (Rearrangements) 100% (6,305x) 10% Replicate (3,781x) 10% Replicate (2,376x) 10% Replicate (2,922x) 5% (2,573x) 2% (2,832x) 1% (3,457x) 0.25% (4,485x) 19
20 Sequencing Run 2 Sequencing Run 2 Comparison of MET Copy Number Analyses Across Sequencing Runs Sequencing (Amplified Samples) R² = Sequencing Run 1 Sequencing (WT Samples) R² = Sequencing Run 1 20
21 Evaluation of MET Amplification in Dilution Series (Copy Number) Global MET Copy Number (Fold) R² = % (4,485x) % 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Tumor DNA Fraction (%) 21
22 A Case Study with Amgen Inc. Detection of Aurora Kinase A (AURKA) Focal Amplification in Plasma Samples of Patients With Recurrent Ovarian Cancer
23 Detection of Aurora Kinase A (AURKA) Focal Amplification in Plasma Samples of Patients With Recurrent Ovarian Cancer The Aurora family of serine-threonine protein kinases (Aurora A, B, and C) regulates key processes in cell division; the genes for these kinases are AURKA, AURKB, and AURKC Aurora kinases are associated with acquired resistance to therapy in human cancers. Hypothesis; AURKA amplification is a late event in ovarian cancer (OC) progression and that the frequency of amplification might be underestimated if assessed in tumor samples collected at the time of initial diagnosis To test this hypothesis, we determined AURKA amplification levels in patients with recurrent Ovarian Cancer (ROC) and compared those to AURKA amplification levels in the same patients at the time of initial diagnosis. Juan G et. al., 2016 AACR 23
24 Study Design Development and analytical validation of a custom AURKADetect Panel Samples were collected from 33 patients with taxane- and platinum-resistant Ovarian Cancer. Patients were enrolled in a phase 1 clinical study that evaluated monotherapy with AMG 900, an orally administered pan-aurora kinase inhibitor (NCT ) AURKA FISH testing in formalin-fixed, paraffin-embedded (FFPE) tumor tissues collected at time of primary diagnosis. Use of AURKADetect to identify AURKA amplifications in plasma samples at the time of study enrollment. Juan G et. al., 2016 AACR 24
25 AURKADetect Analytical Validation Data Case Type Experimental Tumor Purity (%) Average Total Coverage AURKADetect Result Plasma from Healthy Individual - 5,272 Wild-Type Plasma from Healthy Individual - 4,317 Wild-Type Plasma from Healthy Individual - 4,130 Wild-Type BT-474 (Cell Line) % 6,998 Amplified BT-474 (Cell Line) % 7,825 Amplified BT-474 (Cell Line) % 8,103 Amplified BT-474 (Cell Line) % 7,370 Amplified BT-474 (Cell Line) 10.00% 3,996 Amplified BT-474 (Cell Line) 2.00% 3,920 Amplified BT-474 (Cell Line) 1.00% 3,070 Amplified BT-474 (Cell Line) 0.50% 3,040 Amplified BT-474 (Cell Line) 0.20% 2,928 Amplified 10% 2% 1% 0.5% 0.2% Juan G et. al., 2016 AACR 25
26 AURKADetect Results Sample AURKA FISH Percent Mapped to Genome Percent Mapped to ROI Average Total Coverage AURKADetect Result Sample 1 Wild-type 97.7% 50.9% 3,476 Wild-Type Sample % 52.3% 3,294 Wild-Type Sample 3 Wild-type 96.7% 47.3% 3,204 Amplified Sample % 47.7% 3,105 Wild-Type Sample 5 Wild-type 97.3% 47.7% 3,527 Wild-Type Sample 6 Amplified 97.8% 50.0% 3,979 Wild-Type Sample 7 Borderline 97.7% 53.7% 4,114 Amplified Sample 8 Wild-Type 97.7% 64.9% 4,424 Wild-Type Sample 9 Wild-Type 97.2% 64.3% 3,609 Wild-Type Sample 10 F 97.7% 64.9% 4,470 Wild-Type Sample % 67.9% 4,922 Wild-Type Sample 12 F 97.3% 64.6% 3,965 Wild-Type Sample 13 F 97.3% 75.0% 4,462 Wild-Type Sample 14 F 97.6% 59.1% 4,224 Wild-Type Sample 15 Wild-Type 97.9% 66.9% 4,573 Amplified Sample 16 Wild-Type 97.7% 67.8% 4,972 Wild-Type Sample 17 F 97.6% 60.3% 4,172 Amplified Sample 18 Wild-Type 97.7% 56.1% 3,805 Wild-Type Sample 19 F 97.9% 64.7% 5,049 Wild-Type Sample 20 F 98.4% 69.4% 3,832 Amplified Sample 21 Wild-Type 98.0% 69.0% 5,798 Amplified Sample 22 Wild-Type 97.7% 61.0% 5,494 Wild-Type Sample % 65.8% 3,200 Wild-Type Sample 24 F 95.3% 56.9% 3,666 Wild-Type Sample 25 Wild-Type 98.3% 71.8% 4,903 Amplified Sample 26 Wild-Type 97.8% 69.4% 4,839 Wild-Type Sample % 64.9% 3,818 Wild-Type Sample % 64.7% 5,154 Amplified Sample 29 F 97.7% 62.7% 3,725 Wild-Type Sample 30 Wild-Type 96.4% 59.0% 2,129 Amplified Sample 31 Wild-Type 97.9% 64.8% 4,386 Amplified Sample % 65.1% 3,839 Wild-Type Sample 33 Fail 97.9% 60.2% 4,969 Amplified F= Assay Did not Pass QC (-) = No Sample Available or Not Run Juan G et. al., 2016 AACR 26
27 AURKA Amplification is a poor prognostic Factor in ROC PFS 10 weeks longer in WT vs Amp (P = 0.04) OS was 18 weeks longer in WT vs Amp (P = 0.013) Wild-type Amplified Wild-type Amplified Group Median Time Lower 95% CI Upper 95% CI Amplified Wild-type Combined Group Median Time Lower 95% CI Upper 95% CI Amplified Wild-type Combined Juan G et. al., 2016 AACR 27
28 AURKA Study Conclusions AURKA amplification more common in patients with a higher number of prior lines of therapy AURKA amplification likely to be a late event in ovarian cancer progression Detection of AURKA focal amplification in plasma is a highly sensitive method; cfdna is an appropriate material for this type of analysis Evaluation of AURKA amplification by sequencing of plasma DNA allows the noninvasive assessment of acquired resistance to cancer therapy. Observed a correlation between AURKA amplification and PFS and OS: development of AURKA amplification may be indicative of poorer patient outcomes, with shorter PFS and OS Juan G et. al., 2016 AACR 28
29 Acknowledgments Epizyme Scott R. Daigle Scott Ribich Heike Keilhack Peter T. Ho Stephen J. Blakemore Institut Bergonie, Bordeaux, France Antoine Italiano Insitut Gustave Roussy, Villejuif, France Vincent Ribrag Amgen Inc. Gloria Juan Katherine Paweletz Abraham Anderson Erick Gamelin Gregory Friberg Robert Loberg Florian D. Vogl Personal Genome Diagnostics Samuel Angiuoli Sian Jones Mark Sausen 29
30 Agilent products described are For Research Use Only. Not for use in diagnostic procedures. 30
SureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationInternational Conference on Malignant Lymphoma (ICML) June 14-17, 2017
International Conference on Malignant Lymphoma (ICML) June 14-17, 2017 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR: CLINICAL ACTIVITY AND FAVORABLE SAFETY IN PATIENTS
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationCAPP-seq. Davide Rossi, M.D., Ph.D.
CAPP-seq Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CAPP-seq capture and sequencing approach Exon
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationParticipating Institutions Insitut Gustave Roussy, Villejuif, France Institut Bergonie, Bourdeaux, France. Sponsor Epizyme, Inc
Phase 1 Study of EPZ-6438 (E7438), an Enhancer of Zeste Homolog-2 (EZH2) Inhibitor: Dose Determination and Preliminary Activity in Non-Hodgkin Lymphoma V. Ribrag, J-C. Soria, B. Thomson, L. Reyderman,
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationA complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationA Phase 1 Study of Tazemetostat (EPZ-6438), an Enhancer of Zeste-Homolog 2 (EZH2) Inhibitor: Preliminary Activity in INI1-Negative Tumors
A Phase 1 Study of Tazemetostat (EPZ-6438), an Enhancer of Zeste-Homolog 2 (EZH2) Inhibitor: Preliminary Activity in INI1-Negative Tumors A Italiano, H Keilhack, M Toulmonde, J-M Coindre, J-M Michot, C
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationSingle-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) DNA Supplementary Materials
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationAdvance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library
Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationACTIVITY 2: EXAMINING CANCER PATIENT DATA
OVERVIEW Refer to the Overview of Cancer Discovery Activities for Key Concepts and Learning Objectives, Curriculum Connections, and Prior Knowledge, as well as background information, references, and additional
More informationAD (Leave blank) TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients
AD (Leave blank) Award Number: W81XWH-12-1-0444 TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients PRINCIPAL INVESTIGATOR: Mark A. Watson, MD PhD CONTRACTING ORGANIZATION:
More informationIdentification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins
Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins February 3-5, 2016 Lansdowne Resort, Leesburg, VA Molecular
More informationSupplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols.
Supplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols. A-tailed DNA was ligated to T-tailed dutp adapters, circularized
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationUrinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015
Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of
More informationPerformance Characteristics BRCA MASTR Plus Dx
Performance Characteristics BRCA MASTR Plus Dx with drmid Dx for Illumina NGS systems Manufacturer Multiplicom N.V. Galileïlaan 18 2845 Niel Belgium Table of Contents 1. Workflow... 4 2. Performance Characteristics
More informationDetecting Oncogenic Mutations in Whole Blood
WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The NSABP Foundation
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationCirculating tumour DNA in breast cancer. Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho
Circulating tumour DNA in breast cancer Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho Conflicts of Interest I have no financial relationships to disclose I will
More informationCLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases
CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases Adriana Muniz 1, Mariko Matsutani 1, Karena Kosco 1, John Spinosa 1, Cecile
More informationIdentification of BRAF mutations in melanoma lesions with the Roche z480 instrument
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationBCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL)
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Fig. 1: Quality assessment of formalin-fixed paraffin-embedded (FFPE)-derived DNA and nuclei. (a) Multiplex PCR analysis of unrepaired and repaired bulk FFPE gdna from
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationMyeloma Genetics what do we know and where are we going?
in partnership with Myeloma Genetics what do we know and where are we going? Dr Brian Walker Thames Valley Cancer Network 14 th September 2015 Making the discoveries that defeat cancer Myeloma Genome:
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationHarnessing Killer T Cells
Harnessing Killer T Cells Julie Nielsen, PhD BC Cancer Agency May 2, 2015 Overview The immune response to cancer What T cells are & how they work Immune-based therapies for cancer Using T cells to target
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationSupplementary Figure 1
Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationImportance of minor TP53 mutated clones in the clinic
Importance of minor TP53 mutated clones in the clinic Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Reserach Bellinzona - Switzerland
More informationVertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients
Vertical Magnetic Separation of Circulating Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients Chang Eun Yoo 1,2#, Jong-Myeon Park 3#, Hui-Sung Moon 1,2, Je-Gun Joung 2, Dae-Soon Son
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationFollicular Lymphoma It s not just the t(14;18) anymore. UK Cytogenetics, Newcastle. Jude Fitzgibbon
Follicular Lymphoma It s not just the t(14;18) anymore UK Cytogenetics, Newcastle Jude Fitzgibbon Centre for Haemato-Oncology 16 th March 2015 Technology has Improved Late 80s: My First PCRs by Water bath.
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationFrequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Non-Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma Hae Yong Yoo, 1,2 * Pora Kim, 3 * Won Seog Kim, 2,4 * Seung Ho Lee, 1 * Sangok Kim, 3,5 *
More informationThe Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw
The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw Introduction The CRUK Stratified Medicine Programme: SMP1 rationale, design and implementation The role of the cellular
More informationAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage Aaron M Newman1,2,7, Scott V Bratman1,3,7, Jacqueline To3, Jacob F Wynne3, Neville C W Eclov3, Leslie A Modlin3,
More informationLaboratory Service Report
Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationMYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival
in partnership with MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival Brian A Walker Centre for Myeloma Research,
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationSeptember 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development
The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development September 23, 2016 Anand Pathak, MD, PhD, MPH Medical Officer Molecular Genetics Branch Division of Molecular Genetics and
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationLiquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System
Liquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System Erwin Sablon, Head of R&D, Biocartis NV World CDx, Boston, September 10 th 2015 0 About Biocartis Innovative molecular
More information